Urogen Pharma Ltd (NASDAQ:URGN) COO Stephen Mullennix sold 608 shares of Urogen Pharma stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $26.00, for a total transaction of $15,808.00. Following the completion of the transaction, the chief operating officer now owns 8,291 shares of the company’s stock, valued at approximately $215,566. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
URGN stock traded down $0.48 on Monday, hitting $26.09. The company’s stock had a trading volume of 177,823 shares, compared to its average volume of 204,772. The firm has a 50 day moving average of $22.96 and a two-hundred day moving average of $31.61. Urogen Pharma Ltd has a 1 year low of $20.72 and a 1 year high of $55.49. The stock has a market cap of $549.59 million, a price-to-earnings ratio of -5.44 and a beta of 1.12.
Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.06) EPS for the quarter, beating the consensus estimate of ($1.26) by $0.20. Analysts predict that Urogen Pharma Ltd will post -4.79 earnings per share for the current fiscal year.
A number of research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, October 26th. ValuEngine upgraded shares of Urogen Pharma from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. JPMorgan Chase & Co. dropped their target price on shares of Urogen Pharma from $40.00 to $39.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 13th. Stifel Nicolaus set a $41.00 target price on shares of Urogen Pharma and gave the company a “buy” rating in a research report on Sunday, October 20th. Finally, Oppenheimer cut their price target on shares of Urogen Pharma from $70.00 to $62.00 in a research note on Wednesday, November 13th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $51.86.
Hedge funds have recently added to or reduced their stakes in the stock. ARK Investment Management LLC increased its stake in Urogen Pharma by 50.2% in the 2nd quarter. ARK Investment Management LLC now owns 13,529 shares of the company’s stock valued at $486,000 after buying an additional 4,522 shares during the period. Parametric Portfolio Associates LLC acquired a new position in Urogen Pharma in the 2nd quarter valued at $219,000. Highline Capital Management L.P. increased its stake in Urogen Pharma by 2.8% in the 2nd quarter. Highline Capital Management L.P. now owns 1,014,078 shares of the company’s stock valued at $36,446,000 after buying an additional 27,200 shares during the period. LLBH Private Wealth Management LLC increased its stake in Urogen Pharma by 76.9% in the 2nd quarter. LLBH Private Wealth Management LLC now owns 17,692 shares of the company’s stock valued at $636,000 after buying an additional 7,692 shares during the period. Finally, BlackRock Inc. increased its stake in Urogen Pharma by 216.8% in the 2nd quarter. BlackRock Inc. now owns 1,338,553 shares of the company’s stock valued at $48,107,000 after buying an additional 915,970 shares during the period. Hedge funds and other institutional investors own 73.27% of the company’s stock.
Urogen Pharma Company Profile
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Read More: What is the Bid-Ask Spread?
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.